Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk-stratified groups according to the new Cutaneous Lymphoma International ...

The T-cell Malignancies market offers significant opportunities with over 75 companies and 80+ drugs in the pipeline, exploring novel treatments like CAR-T therapies and targeted therapies. Despite ...

Learn about Anaplastic Large-Cell Lymphoma (ALCL), including its causes, symptoms, diagnosis and treatment options for better ...

The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...

New research challenges the status quo that cancer treatments are responsible for accelerating the aging process, indicating that cancer itself also plays a role. A team of researchers from Moffitt ...